Hoth Therapeutics, Inc. (HOTH)
| Previous Close | 1.1600 |
| Open | 1.2100 |
| Bid | 1.1100 x 100 |
| Ask | 1.2400 x 100 |
| Day's Range | 1.1500 - 1.2100 |
| 52 Week Range | 0.9900 - 4.3000 |
| Volume | |
| Avg. Volume | 447,306 |
| Market Cap | 5.818M |
| Beta (5Y Monthly) | 0.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3000 |
| Earnings Date | May 15, 2024 - May 19, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.67 |
PR NewswireHoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,500,000 shares of common stock of the Company originally issued in January 2023, having an exercise price of $5.00 per share, at a reduced exercise price of $1.6775 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant
- PR Newswire
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its subsidiary, Merveille.ai, in the field of obesity treatment. Utilizing advanced artificial intelligence, Merveille.ai has identified a promising new therapeutic candidate, culminating in a strategic patent filing.
ZacksHoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
Hoth Therapeutics (HOTH) rises on encouraging pre-clinical data demonstrating cognitive benefits of its novel therapeutic candidate, HT-ALZ, in the treatment of Alzheimer's disease.
